MedPath

Clinical trial on prevention as well as reduction of chemotherapy-induced neuropathy with acupuncture treatment on the breast cancer patients

Not Applicable
Conditions
Chemotherapy-induced peripheral neuropathy
Registration Number
ITMCTR2200006866
Lead Sponsor
Jiangsu Provincial Hospital of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

(1) Patients with histological diagnosis of stage I-III breast cancer, excluding distant metastases
(2) Patients who plan to receive adjuvant or neoadjuvant chemotherapy (with or without HER-2 targeted therapy) must be enrolled before the second adjuvant chemotherapy.
(3) Over 18 years of age
(4) Sign informed consent
6. No serious organic damage to heart, kidney, liver or brain;
7. Signed the informed consent, participated in and randomly assigned to a study group with no history of substance abuse, and actively cooperated with treatment and follow-up.

Exclusion Criteria

(1) Previous CIPN-causing chemotherapy (one dose of chemotherapy allowed).
(2) There were unstable heart disease and myocardial infarction in the first six months
(3) Have a pacemaker or implantable cardioverter defibrillator
(4) Uncontrollable seizures
(5) Prior peripheral neuropathy (PRO-CTCAE CIPN Scale)
(6) Acupuncture within three months before enrollment

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
EORTC QLQ-CIPN20 scale mean change value;
Secondary Outcome Measures
NameTimeMethod
QLQ-C30 Scale;KPS;NRS Scale;
© Copyright 2025. All Rights Reserved by MedPath